Sparrow Cleared to Start Phase 2 Trial of SPI-62 Early Next Year

Sparrow Cleared to Start Phase 2 Trial of SPI-62 Early Next Year

314284

Sparrow Cleared to Start Phase 2 Trial of SPI-62 Early Next Year

Sparrow Pharmaceuticals is gearing up for the start of a Phase 2 trial that will assess the safety and effectiveness of the company’s experimental medicine SPI-62 in people with Cushing’s disease. The U.S. Food and Drug Administration has cleared Sparrow’s investigational new drug application (IND), giving the company the green light to start testing the therapy in patients. Sparrow is planning to start enrolling participants in the trial early next year. “With the clearance of…

You must be logged in to read/download the full post.